Bod Science Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Bod Science şirketinin kazançları yıllık ortalama -4.2% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 35.1% oranında artan oldu. Gelirler yıllık ortalama 20.2% oranında artan oldu.

Anahtar bilgiler

-4.2%

Kazanç büyüme oranı

14.6%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	31.2%
Gelir büyüme oranı	20.2%
Özkaynak getirisi	n/a
Net Marj	-239.5%
Son Kazanç Güncellemesi	30 Jun 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Bod Science nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

CHIA:BOD Gelir, gider ve kazançlar (AUD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 23	3	-8	4	3
31 Mar 23	4	-7	4	3
31 Dec 22	4	-6	4	2
30 Sep 22	5	-6	5	2
30 Jun 22	5	-5	5	2
31 Mar 22	6	-5	5	2
31 Dec 21	8	-5	5	2
30 Sep 21	8	-5	5	2
30 Jun 21	7	-4	5	2
31 Mar 21	7	-4	4	2
31 Dec 20	7	-5	4	2
30 Sep 20	7	-5	4	2
30 Jun 20	6	-5	3	2
31 Mar 20	4	-6	4	2
31 Dec 19	2	-6	4	1
30 Sep 19	2	-7	5	2
30 Jun 19	1	-8	5	2
31 Mar 19	1	-6	4	2
31 Dec 18	1	-5	3	2
30 Sep 18	1	-4	3	1
30 Jun 18	1	-4	2	1
31 Mar 18	1	-3	2	1
31 Dec 17	1	-3	2	0
30 Sep 17	1	-3	2	0
30 Jun 17	0	-3	2	0
31 Mar 17	0	-3	2	0
31 Dec 16	0	-2	1	0
30 Sep 16	0	-1	1	0
30 Jun 16	0	0	0	0
30 Jun 15	0	0	0	0

Kaliteli Kazançlar: BOD şu anda kârlı değil.

Büyüyen Kar Marjı: BOD şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BOD kârlı değildir ve zararlar son 5 yılda yılda 4.2% oranında artmıştır.

Büyüme Hızlandırma: BOD 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: BOD kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( 26.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: BOD 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Bod Science Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)

Full year earnings released - AU$0.054 loss per share

Recent updates

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

No independent directors

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

New major risk - Negative shareholders equity

New minor risk - Financial data availability

New major risk - Shareholder dilution

Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.

No independent directors

No independent directors

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)

Bod Science Limited Announces Company Secretary Changes

Less than half of directors are independent

Bod Australia Limited Provides Statistical Summary from Its Phase 1 Cannabidiol (CBD) Pharmacokinetic (PK) Study

Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive Director

Less than half of directors are independent

Bod Australia Limited, Annual General Meeting, Nov 28, 2022

Less than half of directors are independent

Less than half of directors are independent

Bod Australia Limited to Launch a New Medicinal Cannabis Product to the Australian Market in July

Less than half of directors are independent

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Announces Board Changes

Bod Australia Limited Advises That It Has Successfully Enrolled First Patients for Its Australian-Based Planned Phase Iib Clinical Trial

Less than half of directors are independent

Bod Australia Limited Announces First Patients Enrolled for Long-Covid Study Investigating the Efficacy of CBD- Dominant Medicinal Cannabis

Bod Australia Announces Board Changes

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new and inexperienced directors

Bod Australia Limited's Novel Food Application Accepted by UK Food Service Agency

High number of new and inexperienced directors

Bod Australia Limited Announces Ethics Approval Received for Schedule 3 Clinical Trial

Bod Australia Limited Announces Secures Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency

High number of new and inexperienced directors

Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)

Bod Australia Limited Launches New CBD -Based Products

Bod Australia Limited Provides Update on New Medicinal Cannabis Product Launch

Chief Financial Officer has left the company

New 90-day low: AU$0.41

Bod Australia Limited Announces the Resignation of Charles Altshuler as Chief Financial Officer, Effective 31 March 2021

New 90-day low: AU$0.42

Bod Australia Limited announced that it expects to receive AUD 8 million in funding

Bod Australia Limited Receives AUD 200,000 Binding Purchase Order from Exclusive Global Partner

New 90-day high: AU$0.58

Bod Australia Limited Announces Strong Growth in Medicinal Cannabis Sales Continues

Bod Australia Limited Launches CBD Products in the Netherlands

Bod Australia Limited Undertakes a Phase I Trial of the Safety Tolerability and Pharmacokinetics of Cannabidiol, Administered in Healthy Volunteers Across Multiple Formulations

New 90-day high: AU$0.51

New 90-day high: AU$0.40

New 90-day high - AU$0.32

Full year earnings released - AU$0.054 loss per share

New 90-day low - AU$0.26

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin